UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study

Haematologica (Roma), 2024-02, Vol.109 (2), p.553

2024

Volltextzugriff (PDF)

PB2304: FIVE‐YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L‐MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e7389505-n/a

2023

Volltextzugriff (PDF)

P1138: FIVE‐YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L‐MIND STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e4580941-n/a

2023

Volltextzugriff (PDF)

P1A Recombinant β-Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin

Antimicrobial Agents and Chemotherapy, 2009-06, Vol.53 (6), p.2455-2462

2009

Volltextzugriff (PDF)

Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e19522-e19522

2023

Volltextzugriff (PDF)

L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years

Blood, 2022-11, Vol.140 (Supplement 1), p.6596-6598

2022

Volltextzugriff (PDF)

Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study

Haematologica (Roma), 2023-08

2023

Volltextzugriff (PDF)

ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S433-S434

2023

Volltextzugriff (PDF)

ABCL-482 Five-Year Subgroup Analysis of Tafasitamab + Lenalidomide From the Phase II L-MIND Study in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S436-S437

2023

Volltextzugriff (PDF)

POSTER: ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S206-S206

2023

Volltextzugriff (PDF)

POSTER: ABCL-482 Five-Year Subgroup Analysis of Tafasitamab + Lenalidomide From the Phase II L-MIND Study in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S206-S206

2023

Volltextzugriff (PDF)

Poster: ABCL-388 L-MIND: Safety and Efficacy of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma on Treatment for at Least 2 Years

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S164

2022

Volltextzugriff (PDF)

ABCL-388 L-MIND: Safety and Efficacy of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma on Treatment for at Least 2 Years

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S375

2022

Volltextzugriff (PDF)

Abstract CT022: Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT022-CT022

2023

Volltextzugriff (PDF)

Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure

American journal of physiology. Heart and circulatory physiology, 2006-05, Vol.59 (5), p.H2007

2006

Volltextzugriff (PDF)

P1A Recombinant ?-Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin

Antimicrobial agents and chemotherapy, 2009-06, Vol.53 (6), p.2455-2462

2009

Volltextzugriff (PDF)

Differential regulation of renal regional blood flow by endothelin-1

American journal of physiology. Renal physiology, 1996-12, Vol.271 (6), p.1166-F1172

1996

Volltextzugriff (PDF)

Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure

American journal of physiology. Heart and circulatory physiology, 2006-05, Vol.290 (5), p.H2007-H2014

2006

Volltextzugriff (PDF)

Regulation of intrarenal blood flow in experimental heart failure: role of endothelin and nitric oxide

American journal of physiology. Renal physiology, 1998-04, Vol.274 (4), p.F766-F774

1998

Volltextzugriff (PDF)

Effects of Eprosartan on Renal Function and Cardiac Hypertrophy in Rats With Experimental Heart Failure

Hypertension (Dallas, Tex. 1979), 1998-10, Vol.32 (4), p.746-752

1998

Volltextzugriff (PDF)

Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure : Role of angiotensin II

Circulation (New York, N.Y.), 1997-11, Vol.96 (10), p.3655-3664

1997

Volltextzugriff (PDF)

Urinary neutral endopeptidase 24.11 activity: Modulation by chronic salt loading

Kidney international, 1995-03, Vol.47 (3), p.855-860

1995

Volltextzugriff (PDF)

Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure

Circulation (New York, N.Y.), 1997-11, Vol.96 (10), p.3655

1997

Volltextzugriff (PDF)

Bosentan improves renal regional blood flow in rats with experimental congestive heart failure

European journal of pharmacology, 1996-08, Vol.310 (2), p.193-196

1996

Volltextzugriff (PDF)

Differential regulation of renal regional blood flow by endothelin-1

American journal of physiology. Renal physiology, 1996-12, Vol.40 (6), p.F1166

1996

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(37)
Buchkapitel
(1)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study

PB2304: FIVE‐YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L‐MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

P1138: FIVE‐YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L‐MIND STUDY

P1A Recombinant β-Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin

Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma

L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years

Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study

ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

ABCL-482 Five-Year Subgroup Analysis of Tafasitamab + Lenalidomide From the Phase II L-MIND Study in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

POSTER: ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

POSTER: ABCL-482 Five-Year Subgroup Analysis of Tafasitamab + Lenalidomide From the Phase II L-MIND Study in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Poster: ABCL-388 L-MIND: Safety and Efficacy of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma on Treatment for at Least 2 Years

ABCL-388 L-MIND: Safety and Efficacy of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma on Treatment for at Least 2 Years

Abstract CT022: Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study

Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure

P1A Recombinant ?-Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin

Differential regulation of renal regional blood flow by endothelin-1

Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure

Regulation of intrarenal blood flow in experimental heart failure: role of endothelin and nitric oxide

Effects of Eprosartan on Renal Function and Cardiac Hypertrophy in Rats With Experimental Heart Failure

Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure : Role of angiotensin II

Urinary neutral endopeptidase 24.11 activity: Modulation by chronic salt loading

Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure

Bosentan improves renal regional blood flow in rats with experimental congestive heart failure

Differential regulation of renal regional blood flow by endothelin-1

Suchergebnisse filtern